Using a safe MRI method to improve heart disease diagnosis in patients with kidney issues
Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart Disease
This study is testing a new, safer MRI method to help doctors better diagnose heart problems in people with kidney issues, using a special substance that doesn't harm the kidneys, so you can get the care you need without extra risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10890627 on NIH RePORTER |
What this research studies
This research focuses on improving the diagnosis of ischemic heart disease (IHD) in patients with chronic kidney disease (CKD) using a new MRI technique that does not rely on harmful contrast agents. The study aims to validate a non-nephrotoxic method that enhances cardiac MRI imaging to accurately assess heart ischemia and viability. By avoiding traditional gadolinium-based contrast, which poses risks for patients with kidney problems, this approach seeks to provide safer and more reliable diagnostic options. Patients will undergo MRI scans that utilize ferumoxytol, a safer alternative, to visualize heart conditions without the associated risks of kidney damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with chronic kidney disease who are at risk for ischemic heart disease.
Not a fit: Patients without chronic kidney disease or those who do not have risk factors for ischemic heart disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more accurate heart disease diagnoses for patients with kidney issues, ultimately improving their treatment outcomes.
How similar studies have performed: Previous research has shown promise in using alternative contrast agents for cardiac imaging, suggesting that this approach may be viable and beneficial.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Nguyen, Kim-Lien T — University of California Los Angeles
- Study coordinator: Nguyen, Kim-Lien T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.